Rising to the challenge: New therapies for tuberculosis

Trends in Microbiology

Volumn 21, Issue 9, 2013, Pages 493-501

  Wong, Emily B ^a,b   Cohen, Keira A ^b   Bishai, William R ^b,c  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b AFRICA HEALTH RESEARCH INSTITUTE   (South Africa)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Bedaquiline; Clofazimine; Delamanid; Oxazolidinones; PA 824; Tuberculosis

Indexed keywords

6,7 DIHYDRO 2 NITRO 6 (4 TRIFLUOROMETHOXYBENZYLOXY) 5H IMIDAZO[2,1 B][1,3]OXAZINE; BEDAQUILINE; BETA LACTAM ANTIBIOTIC; CC 3052; CLOFAZIMINE; CYCLOSERINE; DELAMANID; ETANERCEPT; ETHAMBUTOL; ETHIONAMIDE; GAMMA1B INTERFERON; ISONIAZID; KANAMYCIN; LINEZOLID; MOXIFLOXACIN; OFLOXACIN; OXAZOLIDINONE DERIVATIVE; PLACEBO; PYRAZINAMIDE; RECOMBINANT GAMMA INTERFERON; RIFAMPICIN; SUTEZOLID; TUBERCULOSTATIC AGENT; UNCLASSIFIED DRUG;

BONE MARROW SUPPRESSION; DRUG EFFICACY; DRUG INHIBITION; DRUG RESISTANT TUBERCULOSIS; DRUG RESPONSE; DRUG SAFETY; DRUG TARGETING; DRUG WITHDRAWAL; EXTENSIVELY DRUG RESISTANT TUBERCULOSIS; HUMAN; IMMUNOMODULATION; IMMUNOTHERAPY; LUNG TUBERCULOSIS; MULTIDRUG RESISTANT TUBERCULOSIS; NONHUMAN; OPTIC NERVE DISEASE; PATIENT SELECTION; PERIPHERAL NEUROPATHY; PERSONALIZED MEDICINE; PRIORITY JOURNAL; QT PROLONGATION; REVIEW; SKIN DISCOLORATION; TREATMENT OUTCOME; TUBERCULOSIS; TUBERCULOSIS RAPID TEST;

BEDAQUILINE; CLOFAZIMINE; DELAMANID; OXAZOLIDINONES; PA-824; TUBERCULOSIS;

ANIMALS; ANTITUBERCULAR AGENTS; DRUG DISCOVERY; HUMANS; MYCOBACTERIUM TUBERCULOSIS; TUBERCULOSIS;

EID: 84883789341     PISSN: 0966842X     EISSN: 18784380     Source Type: Journal    
DOI: 10.1016/j.tim.2013.05.002     Document Type: Review

References (76)

1. Lawn S.D., et al. Early mortality among adults accessing antiretroviral treatment programmes in sub-Saharan Africa. AIDS 2008, 22:1897-1908.
2. Wong E.B., et al. Causes of death on antiretroviral therapy: a post-mortem study from South Africa. PLoS ONE 2012, 7:e47542.
3. Rana F.S., et al. Autopsy study of HIV-1-positive and HIV-1-negative adult medical patients in Nairobi, Kenya. J. Acquir. Immune Defic. Syndr. 2000, 24:23-29.
4. World Health Organization Global Tuberculosis Report 2012 2012, WHO.
5. Andrews J.R., et al. Multidrug-resistant and extensively drug-resistant tuberculosis: implications for the HIV epidemic and antiretroviral therapy rollout in South Africa. J. Infect. Dis. 2007, 196(Suppl. 3):S482-S490.
6. Shah N.S., et al. Worldwide emergence of extensively drug-resistant tuberculosis. Emerg. Infect. Dis. 2007, 13:380-387.
7. Gandhi N.R., et al. Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa. Lancet 2006, 368:1575-1580.
8. Cox H.S., et al. Emergence of extensive drug resistance during treatment for multidrug-resistant tuberculosis. N. Engl. J. Med. 2008, 359:2398-2400.
9. Lienhardt C., et al. New drugs for the treatment of tuberculosis: needs, challenges, promise, and prospects for the future. J. Infect. Dis. 2012, 205(Suppl. 2):S241-S249.
10. Andries K., et al. A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis. Science 2005, 307:223-227.
11. Koul A., et al. Diarylquinolines target subunit c of mycobacterial ATP synthase. Nat. Chem. Biol. 2007, 3:323-324.
12. Koul A., et al. Diarylquinolines are bactericidal for dormant mycobacteria as a result of disturbed ATP homeostasis. J. Biol. Chem. 2008, 283:25273-25280.
13. Haagsma A.C., et al. Selectivity of TMC207 towards mycobacterial ATP synthase compared with that towards the eukaryotic homologue. Antimicrob. Agents Chemother. 2009, 53:1290-1292.
14. Rouan M.C., et al. Pharmacokinetics and pharmacodynamics of TMC207 and its N-desmethyl metabolite in a murine model of tuberculosis. Antimicrob. Agents Chemother. 2012, 56:1444-1451.
15. Rustomjee R., et al. Early bactericidal activity and pharmacokinetics of the diarylquinoline TMC207 in treatment of pulmonary tuberculosis. Antimicrob. Agents Chemother. 2008, 52:2831-2835.
16. Diacon A.H., et al. The diarylquinoline TMC207 for multidrug-resistant tuberculosis. N. Engl. J. Med. 2009, 360:2397-2405.
17. Diacon A.H., et al. Randomized pilot trial of eight weeks of bedaquiline (TMC207) treatment for multidrug-resistant tuberculosis: long-term outcome, tolerability, and effect on emergence of drug resistance. Antimicrob. Agents Chemother. 2012, 56:3271-3276.
18. Dooley K.E., et al. Safety, tolerability, and pharmacokinetic interactions of the antituberculous agent TMC207 (bedaquiline) with efavirenz in healthy volunteers: AIDS Clinical Trials Group Study A5267. J. Acquir. Immune Defic. Syndr. 2012, 59:455-462.
19. Andries K.T., et al. Bactericidal potencies of new regimens are not predictive of their sterilizing potencies in a murine model of tuberculosis. Antimicrob. Agents Chemother. 2010, 54:4540-4544.
20. Veziris N., et al. Sterilizing activity of second-line regimens containing TMC207 in a murine model of tuberculosis. PLoS ONE 2011, 6:e17556.
21. Nuermberger E., et al. Powerful bactericidal and sterilizing activity of a regimen containing PA-824, moxifloxacin, and pyrazinamide in a murine model of tuberculosis. Antimicrob. Agents Chemother. 2008, 52:1522-1524.
22. Stover C.K., et al. A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis. Nature 2000, 405:962-966.
23. Singh R., et al. PA-824 kills nonreplicating Mycobacterium tuberculosis by intracellular NO release. Science 2008, 322:1392-1395.
24. Manjunatha U., et al. The mechanism of action of PA-824: Novel insights from transcriptional profiling. Commun. Integr. Biol. 2009, 2:215-218.
25. Tyagi S., et al. Bactericidal activity of the nitroimidazopyran PA-824 in a murine model of tuberculosis. Antimicrob. Agents Chemother. 2005, 49:2289-2293.
26. Diacon A.H., et al. Phase II dose-ranging trial of the early bactericidal activity of PA-824. Antimicrob. Agents Chemother. 2012, 56:3027-3031.
27. Diacon A.H., et al. Early bactericidal activity and pharmacokinetics of PA-824 in smear-positive tuberculosis patients. Antimicrob. Agents Chemother. 2010, 54:3402-3407.
28. Diacon A.H., et al. 14-Day bactericidal activity of PA-824, bedaquiline, pyrazinamide, and moxifloxacin combinations: a randomised trial. Lancet 2012, 380:986-993.
29. Matsumoto M., et al. OPC-67683, a nitro-dihydro-imidazooxazole derivative with promising action against tuberculosis in vitro and in mice. PLoS Med. 2006, 3:e466.
30. Diacon A.H., et al. Early bactericidal activity of delamanid (OPC-67683) in smear-positive pulmonary tuberculosis patients. Int. J. Tuberc. Lung Dis. 2011, 15:949-954.
31. Gler M.T., et al. Delamanid for multidrug-resistant pulmonary tuberculosis. N. Engl. J. Med. 2012, 366:2151-2160.
32. Schecter G.F., et al. Linezolid in the treatment of multidrug-resistant tuberculosis. Clin. Infect. Dis. 2010, 50:49-55.
33. Migliori G.B., et al. A retrospective TBNET assessment of linezolid safety, tolerability and efficacy in multidrug-resistant tuberculosis. Eur. Respir. J. 2009, 34:387-393.
34. Schon T., et al. Wild-type distributions of seven oral second-line drugs against Mycobacterium tuberculosis. Int. J. Tuberc. Lung Dis. 2011, 15:502-509.
35. Koh W.J., et al. Daily 300mg dose of linezolid for multidrug-resistant and extensively drug-resistant tuberculosis: updated analysis of 51 patients. J. Antimicrob. Chemother. 2012, 67:1503-1507.
36. Lee M., et al. Linezolid for treatment of chronic extensively drug-resistant tuberculosis. N. Engl. J. Med. 2012, 367:1508-1518.
37. Sotgiu G., et al. Efficacy, safety and tolerability of linezolid containing regimens in treating MDR-TB and XDR-TB: systematic review and meta-analysis. Eur. Respir. J. 2012, 40:1430-1442.
38. Cox H., Ford N. Linezolid for the treatment of complicated drug-resistant tuberculosis: a systematic review and meta-analysis. Int. J. Tuberc. Lung Dis. 2012, 16:447-454.
39. Gerson S.L., et al. Hematologic effects of linezolid: summary of clinical experience. Antimicrob. Agents Chemother. 2002, 46:2723-2726.
40. Bressler A.M., et al. Peripheral neuropathy associated with prolonged use of linezolid. Lancet Infect. Dis. 2004, 4:528-531.
41. Chang K.C., et al. Linezolid for multidrug-resistant tuberculosis. Lancet Infect. Dis. 2012, 12:502-503.
42. Williams K.N., et al. Promising antituberculosis activity of the oxazolidinone PNU-100480 relative to that of linezolid in a murine model. Antimicrob. Agents Chemother. 2009, 53:1314-1319.
43. Williams K.N., et al. Addition of PNU-100480 to first-line drugs shortens the time needed to cure murine tuberculosis. Am. J. Respir. Crit. Care Med. 2009, 180:371-376.
44. Barry V.C., et al. A new series of phenazines (rimino-compounds) with high antituberculosis activity. Nature 1957, 179:1013-1015.
45. Yano T., et al. Reduction of clofazimine by mycobacterial type 2 NADH:quinone oxidoreductase: a pathway for the generation of bactericidal levels of reactive oxygen species. J. Biol. Chem. 2011, 286:10276-10287.
46. Job C.K., et al. Skin pigmentation from clofazimine therapy in leprosy patients: a reappraisal. J. Am. Acad. Dermatol. 1990, 23:236-241.
47. Zhang D., et al. Identification of less lipophilic riminophenazine derivatives for the treatment of drug-resistant tuberculosis. J. Med. Chem. 2012, 55:8409-8417.
48. Jagannath C., et al. Chemotherapeutic activity of clofazimine and its analogues against Mycobacterium tuberculosis. In vitro, intracellular, and in vivo studies. Am. J. Respir. Crit. Care Med. 1995, 151:1083-1086.
49. Dey T., et al. Outcomes of clofazimine for the treatment of drug-resistant tuberculosis: a systematic review and meta-analysis. J. Antimicrob. Chemother. 2013, 68:284-293.
50. Orenstein E.W., et al. Treatment outcomes among patients with multidrug-resistant tuberculosis: systematic review and meta-analysis. Lancet Infect. Dis. 2009, 9:153-161.
51. Van Deun A., et al. Short, highly effective, and inexpensive standardized treatment of multidrug-resistant tuberculosis. Am. J. Respir. Crit. Care Med. 2010, 182:684-692.
52. Wang F.C., et al. Crystal structure and activity studies of the Mycobacterium tuberculosis beta-lactamase reveal its critical role in resistance to beta-lactam antibiotics. Antimicrob. Agents Chemother. 2006, 50:2762-2771.
53. Hugonnet J.E., Blanchard J.S. Irreversible inhibition of the Mycobacterium tuberculosis beta-lactamase by clavulanate. Biochemistry 2007, 46:11998-12004.
54. Hugonnet J.E., et al. Meropenem-clavulanate is effective against extensively drug-resistant Mycobacterium tuberculosis. Science 2009, 323:1215-1218.
55. Gonzalo X., Drobniewski F. Is there a place for beta-lactams in the treatment of multidrug-resistant/extensively drug-resistant tuberculosis? Synergy between meropenem and amoxicillin/clavulanate. J. Antimicrob. Chemother. 2013, 68:366-369.
56. Payen M.C., et al. Clinical use of the meropenem-clavulanate combination for extensively drug-resistant tuberculosis. Int. J. Tuberc. Lung Dis. 2012, 16:558-560.
57. Paige C., Bishai W.R. Penitentiary or penthouse condo: the tuberculous granuloma from the microbe's point of view. Cell. Microbiol. 2010, 12:301-309.
58. Uhlin M., et al. Adjunct immunotherapies for tuberculosis. J. Infect. Dis. 2012, 205(Suppl. 2):S325-S334.
59. World Health Organization Report of the Expert Consultation on Immunotherapeutic Interventions for Tuberculosis 2007, World Health Organization on behalf of the Special Programme for Research and Training in Tropical Diseases 2007.
60. Condos R., et al. Treatment of multidrug-resistant pulmonary tuberculosis with interferon-gamma via aerosol. Lancet 1997, 349:1513-1515.
61. Johnson J.L., et al. Randomized trial of adjunctive interleukin-2 in adults with pulmonary tuberculosis. Am. J. Respir. Crit. Care Med. 2003, 168:185-191.
62. Suarez-Mendez R., et al. Adjuvant interferon gamma in patients with drug-resistant pulmonary tuberculosis: a pilot study. BMC Infect. Dis. 2004, 4:44.
63. Giosue S., et al. Aerosolized interferon-alpha treatment in patients with multi-drug-resistant pulmonary tuberculosis. Eur. Cytokine Netw. 2000, 11:99-104.
64. Koh W.J., et al. Six-month therapy with aerosolized interferon-gamma for refractory multidrug-resistant pulmonary tuberculosis. J. Korean Med. Sci. 2004, 19:167-171.
65. Dawson R., et al. Immunomodulation with recombinant interferon-gamma1b in pulmonary tuberculosis. PLoS ONE 2009, 4:e6984.
66. Keane J., et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N. Engl. J. Med. 2001, 345:1098-1104.
67. Tsenova L., et al. A combination of thalidomide plus antibiotics protects rabbits from mycobacterial meningitis-associated death. J. Infect. Dis. 1998, 177:1563-1572.
68. Wallis R.S., et al. A study of the safety, immunology, virology, and microbiology of adjunctive etanercept in HIV-1-associated tuberculosis. AIDS 2004, 18:257-264.
69. Subbian S., et al. Phosphodiesterase-4 inhibition alters gene expression and improves isoniazid-mediated clearance of Mycobacterium tuberculosis in rabbit lungs. PLoS Pathog. 2011, 7:e1002262.
70. Maiga M., et al. Risk of tuberculosis reactivation with tofacitinib (CP-690550). J. Infect. Dis. 2012, 205:1705-1708.
71. Helb D., et al. Rapid detection of Mycobacterium tuberculosis and rifampin resistance by use of on-demand, near-patient technology. J. Clin. Microbiol. 2010, 48:229-237.
72. Miotto P., et al. Genotype MTBDRplus: a further step toward rapid identification of drug-resistant Mycobacterium tuberculosis. J. Clin. Microbiol. 2008, 46:393-394.
73. Vilcheze C., Jacobs W.R. The mechanism of isoniazid killing: clarity through the scope of genetics. Annu. Rev. Microbiol. 2007, 61:35-50.
74. Simons S.O., et al. Validation of pncA gene sequencing in combination with the mycobacterial growth indicator tube method to test susceptibility of Mycobacterium tuberculosis to pyrazinamide. J. Clin. Microbiol. 2012, 50:428-434.
75. Ma Z., et al. Global tuberculosis drug development pipeline: the need and the reality. Lancet 2010, 375:2100-2109.
76. Almeida Da Silva P.E., Palomino J.C. Molecular basis and mechanisms of drug resistance in Mycobacterium tuberculosis: classical and new drugs. J. Antimicrob. Chemother. 2011, 66:1417-1430.